# OnCo record us-worldmeds (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/us-worldmeds/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "us-worldmeds" ;
  schema:name "US WorldMeds"@en ;
  schema:alternateName "USWM, LLC"@en, "US WorldMeds"@en, "USWM"@en ;
  schema:description "US WorldMeds is a private Louisville company that took over the engineered T-cell therapies Tecelra and lete-cel from Adaptimmune in 2025 and sells eflornithine (Iwilfin) for maintenance in high-risk neuroblastoma. Whether a small private firm can sustain T-cell manufacturing for a rare sarcoma is the open question."@en ;
  schema:url <https://onco.cc/companies/us-worldmeds/>, <https://www.usworldmeds.com> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://www.usworldmeds.com> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/neuroblastoma/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:drugs <https://onco.cc/drugs/afamitresgene-autoleucel/>, <https://onco.cc/drugs/letetresgene-autoleucel/>, <https://onco.cc/drugs/eflornithine/> .